A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
← catalyst calendarNCT05933200 · readout ≤ 376 d
Sponsored by Ultragenyx Pharmaceutical Inc (industry) · RARE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
69actual
Sites
15
Countries
Czechia, Germany, Japan +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-28 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Interventions
- Drug: Triheptanoin — also filed as UX007, Dojolvi
- Dietary supplement: MCT Oil — also filed as Medium-chain Triglyceride
Primary outcome
what the primary-completion date above is the date OFAnnualized Event Rate of Major Clinical Events (MCEs)
measured Up to Year 4
Permalink · RARE's whole pipeline · Catalyst calendar · Every registered study · What changed